AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01038206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familias Unidas
Description: There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
Study NCT02464306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fidaxomicin
Description: Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
Study NCT01483976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral medical nutritional supplement
Description: orally over a three hour period
Study NCT01483976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental oral medical nutritional supplement with AN777
Description: orally over a three hour period
Study NCT03793205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting G-CSF
Description: Long-acting G-CSF will be given 48 hours after the chemotherapy. A supplement of short-acting G-CSF will be given as required.
Study NCT03793205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-acting G-CSF
Description: Short-acting G-CSF will be given as required 24 hours after the chemotherapy.
Study NCT01747031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PressureWire™ Certus(St. Jude Medical Systems, Sweden)
Description: Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden) will be advanced past the stenosis.
Study NCT04245436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Encapsulated duloxetine 30 mg, 60 mg; once-daily
Study NCT04245436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Encapsulated escitalopram 5 mg, 10 mg, 15 mg, 20 mg; once-daily
Study NCT02454608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil HCl
Description: Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps.
Study NCT02454608 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with the same characteristics (size, color, smell) as Verapamil HCl.
Study NCT02927236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TBS is a type of TMS protocol.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil will be used.
Study NCT02927236 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: TBS is a type of TMS protocol.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil will be used.
Study NCT02927236 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TMS
Description: TBS is a type of TMS protocol.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil will be used.
Study NCT01110551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SC)
Description: Phosphate buffered saline administered subcutaneously.
Study NCT01272050 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.~Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration.
Study NCT01006122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
Study NCT01006122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03654746
Description: Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
Study NCT01110551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (ID)
Description: Phosphate buffered saline administered intradermally.
Study NCT01110551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Live Tetravalent Chimeric Dengue Vaccine (SC)
Description: DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered subcutaneously.
Study NCT03027635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PleurX, peritoneal tunnelated catheter
Description: A permanent catheter
Study NCT03027635 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Large Volume Paracentesis
Description: Short time drainage
Study NCT03027635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 500Mg Tablet
Description: SBP prophylaxis
Study NCT03027635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500Mg Tablet
Description: SBP prophylaxis
Study NCT02146937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide plus Finasteride- Combination therapy
Description: 3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
Study NCT03552978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tech-Facilitated IC Intervention
Description: The Integrated Care (IC) treatment protocol for smoking cessation is a PTSD-informed intervention that has been adapted to be delivered over video or telephone and to incorporate technological components, including the Stay Quit Coach (SQC) smart phone application (app) which is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation. and the coVita Bedfont® Scientific Ltd iCO® Smokerlyzer® device and app which is a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The coVita mobile app is compatible with iOS \&Android and used with the iCO® Smokerlyzer® to display CO readings. Content of sessions is consistent with that delivered in the IC treatment protocol for veteran smokers with post-traumatic stress disorder (PTSD).
Study NCT03552978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Quitline
Description: The SFVAMC's standard of care referral service, known as the VA Quitline which involves weekly telephone sessions through the VA's proactive telephone Quitline, available to all veterans for up to 8 weeks.
Study NCT03385187 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NightOwl HSAT
Description: Patient wears the NightOwl sensor device
Study NCT01244815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)
Study NCT01110551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
Description: DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered intradermally.
Study NCT01244815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match asenapine
Description: Placebo tablets to match asenapine tablets, administered sublingually twice daily
Study NCT01244815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
Study NCT04362592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique
Description: The percutaneous approach uses endoscopes through a closed maternal abdomen and closed uterus to perform the spina bifida correction.
Study NCT04362592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique
Description: The laparotomy/uterine exteriorization technique uses endoscopes through an open abdomen and closed, exteriorized uterus to perform the spina bifida correction.
Study NCT03411031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elotuzumab
Description: Elotuzumab according to dosing schedule outlined in treatment arms.
Study NCT03411031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide according to dosing schedule outlined in treatment arms.
Study NCT03411031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert.
Study NCT00536939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: 1125 milligrams (mg) loading dose on Day 1 of Cycle 1 only then 500 mg oral once daily, until disease progression
Study NCT00536939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: 10 milligrams per kilogram (mg/kg) intravenously, Days 1 and 15 every 28 days, until disease progression
Study NCT00536939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 milligrams per kilogram (mg/kg) intravenously, Days 1 and 15 every 28 days, until disease progression
Study NCT00536939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 90 milligrams per square meter (mg/m\^2), intravenously, Days 1 ,8, and 15 every 28 days until disease progression
Study NCT01461161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bardoxolone methyl
Description: oral, single dose
Study NCT04393779 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HARPOON Beating Heart Mitral Valve Repair System (MVRS)
Description: Repair of the chordae tendinae in the mitral valve.
Study NCT01622088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Oral tablet 150 mg given twice daily (BID)
Study NCT04485793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement
Description: Dietary supplement formulated with 400 mg Bergamot d.e. obtained from different parts of the Citrus Bergamot whole fruit (Citrus bergamia Risso et Poiteau, fructus), specifically from fresh fruits collected from November to February (Brumex TM).~Oral administration: 1 tablet/day at evening meal
Study NCT01244815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
Study NCT01909583 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: STAGES-Booklet
Description: STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
Study NCT00536939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90 milligrams per square meter (mg/m\^2), intravenously, Days 1 ,8, and 15 every 28 days until disease progression
Study NCT00536939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, daily, until disease progression
Study NCT01984333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online cognitive training
Description: Online cognitive training is a web-based video game that offers systematic training of response inhibition capabilities. Participants will be guided to make progress in an individually-tailored fashion to master increasingly difficult game levels.
Study NCT00736697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxidectin
Study NCT01909583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STAGES-Booklet
Description: STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
Study NCT01527825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (seasonal)
Description: Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~* An A/California/7/2009 (H1N1)pdm-like virus~* An A/Perth/16/2009 (H3N2)-like virus\*~* A B/Brisbane/60/2008-like virus \* A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season.
Study NCT01527825 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (seasonal)
Description: Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~* An A/California/7/2009 (H1N1)pdm-like virus~* An A/Perth/16/2009 (H3N2)-like virus\*~* A B/Brisbane/60/2008-like virus \* A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season.
Study NCT01527825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
Study NCT01527825 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
Study NCT04485793 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration: 1 tablet/day at evening meal
Study NCT00396721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor + statin
Description: sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
Study NCT00396721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (study drug)+ACE inhibitor + statin
Description: enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d
Study NCT02592694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocktail
Description: Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration
Study NCT02592694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thrombus aspiration
Description: manual thrombus aspiration
Study NCT02592694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thrombus aspiration
Description: manual thrombus aspiration
Study NCT02529657 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: In 23 randomized patients, LLLT (B-Cure, Good Energies ®, Israel), with CW diode laser - semiconductor Gallium Arsenide and aluminum (GaAlAs) will be applied during surgery (λ = 804 nm ± 2 , total exposure time of 240 s, energy density of 2.48 J/cm2 , average power of 40 mW , spot area of 3,876 cm2), in contact mode, for 60 seconds on the laminectomy site, 60 seconds and 120 seconds in the subcutaneous tissue of the skin over the wound bed, respectively. In the first and second day post surgery, will be collected the drainage output for analysis of interleukin 1, 4, 6, 8 and 10 (IL- 1, IL-4, IL -6, IL-8 and IL -10 ) and tumor necrosis factor alpha ( TNF -alpha ).
Study NCT02529657 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the operating room, lumbar laminectomy will be performed in 46 patients. During the surgery, 24 hours and 48 hours after surgery, the patients received the regular treatment after laminectomy and were induced to thing that were receiving low level laser therapy in their wound.
Study NCT00763984 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT.
Study NCT00763984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder Health class
Description: Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
Study NCT04579497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 38°C warm water footbath
Description: A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 38°C, followed by a ten-minute post-intervention rest period.
Study NCT04579497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40°C warm water footbath
Description: A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 40°C, followed by a ten-minute post-intervention rest period.
Study NCT04579497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 42°C warm water footbath
Description: A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 42°C, followed by a ten-minute post-intervention rest period.